Markets live chat transcript for the chat ending at 12:08 on 11 May 2009. Participants in this chat were: Paul Murphy, FT (PM) Neil Hume, FT (NH)
PM:
This is Markets Live – FT Alphaville’s daily market commentary
PM:
This is the place where we can all congregate to applaud the firm fiscal and monetary leadership that has basically saved the world.
PM:
You can see the relief on people’s faces. Apocalypse avoided – we’re back to climbing that wonderful wall of worry.
PM:
Nah, that will just be credit spreads tightening and gilt yields falling.
PM:
Stocks only go up now. London has adopted the China take.
The Truth! Unvarnished. The price of rice always falls. Shanghai investors do not sell stocks. Torch protestors are vile.
NH:
Well they’re going down today.
NH:
FTSE 100 off 49 points at 4,413
NH:
that said, it was up 5% last week
NH:
miners leading the market down this morning
PM:
In spite of the market move
PM:
Can we not talk a little about green shoots? It was such a nice sunny weekend
NH:
yeah, such a shame the cricket finished early
PM:
Yes, was a shame, since it gave me the chance to spend all of Saturday demolishing a partition wall and carting the bags of rubble down three flights of stairs.
NH:
Much better than sitting in a box at Lords, sipping champagne.
PM:
Anyway, green shoots.
PM:
HSBC Says First-Quarter Profit ‘Well Ahead’ of 2008 (Correct)
PM:
LONDON (Dow Jones)–HSBC Holdings PLC (HBC) said Monday that its U.S. consumer
lending business HSBC Finance Corp. had a better-than-expected first quarter
with loan impairments falling almost 14% from the fourth quarter last year.
Chief Executive Michael Geoghegan told a conference call that the
first-quarter performance in the U.S. had been better than the bank had
anticipated. “It was better (partly) because the tax rebate that people got in
the U.S. was used to pay back debt instead of (being spent on) consumer goods.”
PM:
And look at this – in HSBC Finance – US
PM:
Gain on debt designated at fair value and related derivatives 4,112 1,177
PM:
If HSBC US can book $3bn of profit revaluing their own debt, how can we not have green shoots??????????
NH:
debt gone down in value then? after a £12.5bn rights issue
PM:
Actually, I’ll stop messing about.
PM:
Truth is we haven’t had a change to look at those HSBC Q1 figures properly yet.
PM:
Suffice to say, they’ve gone down rather badly – stock is off almost 4 per cent.
PM:
All the banks have taken a bath – although their bath is not quite a deep as the miners’
NH:
actually on HSBC I have some reaction
NH:
first bit I have seen
NH:
from Nomura, who else.
NH:
The HSBC statement shows trends similar to expectations. However, other than the financials revealed by the US subsidiaries, the group has given relatively little in terms of hard numbers and clear conclusions are difficult to draw, particularly ahead of the conference call. The outlook statement contains little by way of forward looking guidance; it does comment that business confidence and investor risk appetite may have improved, although the outlook remains highly uncertain.
NH:
Group Q1 profits were said to be lower ex own debt gains, with impairments higher; this is not a surprise and is consistent with our estimates, although there is little indication of how much. The group does indicate that it generated capital ahead of the run rate in the second half of the year and more than covered the interim dividend of 0.08c.
NH:
The statement comments that US charges were lower than expected. HSBC Finance charges were $3.95bn-this is $1bn lower than we have in our estimates. HSBC Finance 2+ delinquencies were essentially flat on the year end-up just $100m. However, much of this is likely to be seasonal; 2+ delinquency increased just $400m in Q1 last year. At the same time, HSBC Finance profits before credit impairment were $2.2bn ex own debt gains, well below our assumption of $3bn per quarter.
NH:
AFS reserves on the ABS book fell modestly by $700m; the book also fell.
GBM was reported to have enjoyed a record quarter and these trends have continued into April.
Q1 benefited from $6.5bn of own debt gains ($4bn in HSBC Finance), but these have substantially reversed since then.
NH:
The statement refers to margin pressure from lower rates on deposits, offset by strong balance sheet revenue in GBM.
Risk weighted assets declined from the level at the end of last year and the core equity tier 1 ratio was also ahead at 8.6% at the end of the first quarter.
NH:
so, the gain is likely to have disappeared
NH:
in the month of April
NH:
now you see it, now you don’t
NH:
talking of magin, I have just seen something else amazing
NH:
one of Paul’s small cap favs
Futuragene (FGN:LSE): Last: 55.36, down 0.64 (-1.14%), High: 57.80, Low: 55.25, Volume: 23.75k
NH:
signed an intriguing deal last week with a company that was hiding behind a Delware Inc company
PM:
This is not about bugs mixed with seeds — its simple cross breeding of plants
NH:
they have taken a 10% stake
PM:
Developed from the decoding of the planet genome
PM:
I love(d) this company.
PM:
Tipped it all way down from 150
PM:
Four years later it finally launches a decent rally
PM:
Dont chase it now tho
PM:
aNYWAY — GETTING DISTRACTED
PM:
Let’s do RAW early in the session
RAW is market chatter – information that has not been formally tested through traditional journalistic channels (PRs etc). The story might be complete rubbish, but if we believe there is some substance to it we will say so. Either way, Reader Beware.
PM:
What have you got Neil??
NH:
two bits of rumourtrage
NH:
now, what shall we start with?
NH:
did you read the Sindy yesterday?
NH:
but a broker was kind enough to point me in the direction of this story
NH:
A mystery European investor is set to challenge the board of Tate & Lyle, the struggling sugar refiner after amassing a “sizeable economic interest” in the company through equity derivative contracts.
Stock lending sources say that an activist is looking to “further shake-up” the management of the ailing business, which has issued two profit warnings in the past two months. However, the individual is not thought to be looking to pursue a full takeover. The buyer is understood to have a position worth more than 15 per cent of the company’s shares.
NH:
Under current rules investors can secretly ambush companies by purchasing up contracts for difference (CFDs), which allow investors to get direct exposure to a company’s share price, but does not confer voting rights.
PM:
so a secret stakebuilder on loose
PM:
intriguing, especially given that one of Tate’s biggest shareholders is the Midas of Misery
PM:
Philip Falcone of Harbinger
NH:
indeed, although he has been selling down in recent months
NH:
holding stands at 13%
PM:
so, is there any indication that a secret stakebuilder has been at work?
NH:
volumes have not been massive of late
NH:
and looking at the share register there does not seem to be stakes held through prime brokers that add to 15% but…
NH:
well, there have been rumours for a couple of months now that a mysterious overseas investors was trying to get its hands on a big block of Tate
NH:
he approached several broking houses, many of whom turned the business away
NH:
but he did get on somewhere
PM:
and who is the person??
NH:
look this is RAW, but the name in the frame is a Portugese financier
NH:
who goes by the name of Joao V Azevedo
NH:
he was the president of Benefica for a time and seems to control a private equity company in the UK
NH:
that appears to have been in the headlines at home
NH:
here’s his biog from a the site of the private equity group V&A Capital
NH:
parts of which do not work at the moment, which is somewhat strange
NH:
Joao V Azevedo, 1957 (Portuguese), holds a Law Degree from the Law School of Lisbon (Portugal), University of Lisbon. Qualified lawyer admitted to the bar in 1980. Member of the Portuguese Bar Association, International Bar Association, European Lawyer’s Union, American Bank Attorneys and Young Lawyers International Association (AIJA). He was Junior Assistant at the Lisbon Law University (1979-1981); Portuguese Prime Minister’s Legal Advisor (1981-1983), founder, senior and managing partner of Vale e Azevedo & Associados, one of the biggest Portuguese law firms (1983-2002); corporate finance advisor of the Portuguese Industrial Association (1983-1997); chairman and CEO of Vale e Azevedo Capital, SA a corporate finance and venture capital company (1983-2001); chairman and CEO of Sojifa, SA and Marden Enterprises Corporation, real estate developers (1988-2001); member of the board of Calgás Portugal, SA a company belonging to the Spanish group Gas Natural (1988-1997); and President of SL Benfica , the main Portuguese Football Club (1997-2000). Since 1984 he is shareholder and member of several strategic boards and committees of Copam, SA the Portuguese starch company. He is also a member of advisory boards of various other business operations in Europe.
PM:
that would be the link
NH:
well, strach is in the same area
NH:
though Tate may have sold out
NH:
it looks to be listed
NH:
yeah, its shares don’t trade much either
NH:
if this guy is building a position in Tate
NH:
he must have some backing from elsewhere
NH:
15% of the company is worth around £200m
PM:
OK, we will be keeping tabs on this one
PM:
looking for any big blocks of stocks changing hands
NH:
on the watch page already
PM:
and the other piece of RAW ??
NH:
could be a good story this
NH:
comes from some reasonable bandits
NH:
this could be interesting
NH:
the word in the market is that the company has received an approach for non-regulated activities
NH:
which comprises as far as I can see does outsourcing
NH:
although what it does I can’t quite tell
NH:
We apply our core skills of our regulated business through our outsourcing contracts, now serving more than 20 million people worldwide across Europe, the Middle East, Australia and the Philippines. We also operate a highly successful multi-utility connections business, manage metering contracts and are flexing our engineering and operational skills in emerging markets such as muncipal solid waste.
We have major contracts in the UK with Dwr Cymru Welsh Water, Southern Water, Scottish Water, Northern Gas Networks and Electricity North West. We have a meter installation contract with British Gas Trading, as well as three Scottish private finance initiative operations relating to water and wastewater infrastructure.
We are focusing on applying our core skills on an asset-light basis, primarily in the Gulf region but we also continue to operate existing overseas water and wastewater operations through a number of joint ventures in parts of Australia, Estonia, Bulgaria, the Philippines and Poland.
NH:
anyway, the point is that someone has offered £1bn for this business
NH:
well that’s according to the RAW
PM:
any idea who the bidder is??
NH:
yes, private equity, 3i
NH:
and that’s why I am treating the story with some caution
NH:
yes, I know 3i has just announced plans to raise 3700m via a cash call
NH:
and the green shoots of recovery are appearing
PM:
yeah, that’s quite an ask
NH:
but, it is possible UU might sell
NH:
the company is highly geared, even for a utility
NH:
market capitalisation is around £3.6bn at the moment
PM:
and what do sector watchers make of all this??
NH:
possible but unlikely
PM:
But then analysts always say that when it comes to corporate activity
PM:
notoriously poor at spotting it
NH:
UU have stated in the past that the non-reg business is core
NH:
analysts value the business at around £670m, so a £1bn looks toppy
NH:
equates to around 20 times earnings
PM:
a top of the market multiple
NH:
but UU does have a lot of debt, even for a utility
NH:
and that’s down to the fact it returned £1.5bn to shareholders less than a year ago
NH:
however, as the company will no doubt point out, its debt to RCV is in line with Ofwat numbers.
PM:
Note Pakora’s suggestion below…
PM:
The whole story warrants further investigation i think
PM:
While we are doing RAW, we should congratulate City Unslicker below
PM:
Mentioned African Copper on his blog and below here on Friday
PM:
African copy have come out with a financing deal worth 2o odd million
PM:
it’s being acquired by Zambian Copper Investments
PM:
Stock is up a cool 73% at 7/7.25
NH:
I think he deserves a bandit rating for that. what shall we start him at? one small cap bid target out of one right.
PM:
Oh yes, Bandit rating for City Unslicker
PM:
What shall we give him?
NH:
hmmmmmmmm,

NH:
then again this is a microcap company
PM:

, on positive outlook watch
NH:
in line for upgrade with another good shout
NH:
(Fitz, the scale works in the other direction – one is god like bandit)
PM:
anything else to look at ?
NH:
we have done lots on the dash for trash recently
PM:
yep, Tracy did a good post early this morning
PM:
Charting the Suckers rally
NH:
well, there is mounting evidence that the dash for trash can harm your financial wealth
PM:
burnt fingers from trash being incinerated
NH:
handle trash with care, especially the toxic stuff
NH:
plant hire company with most of operations in the US
NH:
also fairly highly geared
PM:
a pretty toxic combination
NH:
well, because of all this green shootery nonsense the stock has shot higher in the past couple of months
NH:
33p at the start of March and rose steadily hitting 65p last week
NH:
unscheduled trading update
NH:
stock down 13.5p at 50.5p
NH:
yep, very painful this
NH:
so, the company’s financial year runs to April
NH:
and in the fourth quarter of the year, sales fell off a cliff – down 24%
NH:
but here’s the interesting bit, instead of green shoots, Ashtead does not expect things to get any better and is warning on profits for the year to April 2010
NH:
anyway, here’s a couple of notes
NH:
Ashtead – [AHT.L AHTLN] 63p Underperform – Profit warning
Ashtead has this morning released an unscheduled trading update, detailing trading behind expectations and warning that profits for FY to April 2010E are likely to be behind current expectations. Interestingly, the group says that it expects profits for the year to be at the bottom end of expectations, where the range is very wide but excluding outliers, the statement gives an £85m – £95m range. Next year’s (2010E) PBT consensus from Reuters is £58.8m with a range of £48m – £80m.
NH:
The current run rate is showing volumes in line with management’s expectations despite particularly weak private sector trading. Rental rates are however deteriorating at a faster rate than management anticipated. This is concerning news as falls in rental rates are particularly costly given that there is little in the way of costs that reduce with the revenues. By comparison, falls in utilisation rates are generally accompanied by reduced maintenance and transport costs.
The statement carries a comment that Q4 revenues were down YoY by 24% in constant currency terms. It is worth bearing in mind that currency has moved against the group somewhat in recent weeks and that will have a significant impact on a company that has historically generated 90% of profits in the US.
NH:
2010E estimates will therefore need to come down and potentially significantly pending a conversation with management.
The shares have rallied 43% in the last month and look very exposed on 7.8x on old estimates. We looked in our sector report last week (attached) at the timing of a sustainable bounce in Ashtead’s share price and concluded that it has only happened in the last two cycles when the FTSE as a whole has bounced. As we do not believe that the current rally is sustainable, Ashtead’s share price is likely to be weak and trading conditions are likely to continue to be very weak for the next few months, so further estimate cuts are very possible.
We retain our UNDERPERFORM recommendation.
NH:
A trading update from Ashtead suggests profits for the year just ended will be
at the lower end of current expectations, and that our expectations for the
current year may also be too high. Clearly, share prices in Tool Hire
companies have got ahead of themselves in recent weeks – it remains tough
out there. Economic conditions remain difficult, and while there are reduced
covenant concerns on Ashtead, debt remains high. With a large US bias
Ashtead should see any recovery before more UK oriented players, so this
sends a chill wind over valuations for others like Speedy Hire. We remain
Sellers of Ashtead.
NH:
Update: Profits for the year just ended look to be at the lower end of expectations, and
some way short of our £95.4m as a result of ongoing economic pressure and more
difficult weather than previous years. Debt looks slightly lower than our f/c at £1040m
(f/c £1057m).
Outlook: Private sector projects in the US and the UK remain under pressure through
lack of funding, though cost reductions have exceeded earlier management expectations (which should help the current year). Government financed infrastructure projects remain in place and Ashtead believes it has gained market share, though with
deteriorating rental rates conditions may remain difficult for some time. A -24% L4L
revenue number in Q4 suggests things getting tougher rather than easier for the short -term
at least.
NH:
Forecasts & Recommendation: In the light of comments regarding 2010 now being
below previous management expectations our current £53.5m remains under review.
Nevertheless, we suspect the range of forecasts currently in the market to reduce
markedly (£45-80m?). Cashflow should remain positive, with an indication of at least a further £100m net positive cashflow in the current year (our forecast under review
shows £128m), and with long term finance and no eps based covenants finances look
relatively strong. Nevertheless, any trading improvements look to be some way off.
We reiterate our negative view on Ashtead ahead of any change in current forecasts (only likely to be downwards) and target price of 35p.
PM:
and of course Ashtead is not the only piece of cyclical trash where the bulls are nursing burnt fingers this morning
NH:
well, that’s what happens if you ask shareholders for $450m in cash and at the same time release a dismal trading statement
NH:
actually the fact that Lonmin’s operation performance is dismal should surprise no one
NH:
it has been that way for a while, so much so that they had to get rid of the CEO
NH:
I read somewhere this morning that the platinum price needs to be a $1,200 an ounce before they are profitable
PM:
just brought up the chart on Lonmin
PM:
no wonder they decided to launch a cash call
PM:
just look at the price performance
PM:
starts the year around £10 and then whoosh
NH:
and the cash call follows
NH:
actually they are lucky that two big shareholders are prepared to back this
NH:
Xstrata and M&G – they own 35% of the company
NH:
right, here’s a few bits of comment on Lonmin
NH:
right, here’s a note from Citigroup which highlights the dismal operating performance of Lonmin quite well
NH:
H1 09 results — EBITDA came in at a $51m loss (Citi -$31m loss, Consensus
-$18m loss) and PAT at a $97m loss (Citi -$10m, Consensus -$23m). No
interim dividend. Citi is currently forecasting a full-year loss of $66m. H2 now
looks more positive than our original assessment.
Costs on the mend — Cost per PGM ounce produced at R6956 was 26.7%
higher than the first half of 2008 but was 1% down on the preceding 6 months
to Sept-08 and is set to reduce further as the benefits of the restructuring
program kick in during H2. Monthly cost trends are now improving steadily.
Cost guidance — Lonmin had previously forecast total 2009 Rand-based gross
operating costs for the full year to increase, but at a slower rate than South
African inflation. New guidance is for these total costs to actually be lower than
the 2008 total, in spite of the big wage increases in the interim.
NH:
Production — Guidance is maintained at 700,000oz for this year. We believe
that Lonmin has now turned the corner and expect substantial productivity and
cost improvements. Furthermore H1 losses were incurred at a platinum price
of $947/oz; current spot is 21% higher at $1150/oz.
Assessment — We rate LMI Hold/High Risk because of the past operational
problems but we would need to seriously assess the early signs of productivity
progress.
Rights issue — 2 for 9 at £9.00 raising $457m. Use of proceeds primarily to
reduce debt. LMI had net debt of $449m at 31/3/09 and has $975m of
committed facilities in place, with $575m of these comprising new facilities. A
good time for a rights issue, even if not desperately needed, in our opinion
NH:
Lonmin reported an underlying loss of US$0.50/sh/ above BAS-ML of US$0.60/sh an below Reuters consensus of US$0.23/sh
The company also announced a 2 for 9 rights issue with a subscription price of
900p to raise proceeds of approximately US$457m
Key points:
- 6,400 full time employees and contractors have been retrenched with one-off
costs of $44 million and expected annualised cost benefits of $90 million
NH:
- Maintaining 2009 full year sales guidance of around 700,000 Platinum ounces
- Costs up 27% to ZAR6,956/PGM oz however monthly cost trend towards the
end of the first half of 2009 showing improvement, with costs trending down
- No dividend declared, in-line with BAS-ML forecast
Outlook:
- Expecting Rand-based gross operating costs for 2009 to be lower than incurred
in 2008
- Short term demand outlook remains uncertain, jewellery not enough to
compensate for auto demand destruction
The stock could open down on these results and the rights issue
NH:
Lots of questions below about the Panorama prog into Stanford
NH:
which was supposed to be on last Monday and got pulled at the last minute
PM:
Well Wont get Stacy’s views until this afternoon. She was just on her way back last night from a family thing at the weekend.
PM:
We don’t know more than the BBC story
PM:
Seems sensible that if Stanford was a Texan running a Caribbean bank that the US authorities would try to use him for information on drug money
PM:
But whether that all adds up to him being a CIA spy and the whole thing being a front bank — well ive no idea obviously
NH:
does that explain why he has not been charged by the FBI
NH:
only the SEC and that’s not a criminal offence
NH:
a few lawyer hours must have gone into that
NH:
what about International Personal Finance
PM:
ah, the emerging markets doorstep lender
PM:
seen a good note on that this morning
NH:
and they haven’t complained about being called a doorstep lender yet
PM:
Draws attention to the banking covenants — and the fragility of …
NH:
not surprised by that
NH:
for those of you who were not around on Friday
NH:
IPF is a doorstep lender with a twist
NH:
it operates in emerging markets – primarily Mexico and eastern Europe
NH:
anyway it issued a thumping profit warning on Friday and its share price duly collapsed
PM:
and it is on the slide again this morning
PM:
another 12% sliced off its market cap
NH:
In addition to the covenants jitters
NH:
Friday’s post results conference call went badly. Very badly
NH:
it seems the company had no idea that it had big problems in Hungary until a couple of days ago
NH:
then it seemed surprised that some of their customers in Hungary were struggling to repay their debts because they had taken out Swiss franc mortgages
NH:
and to cap it all off
NH:
they tried to tell analysts there would be no read across to other Poland and other markets in Eastern Europe, where we all know swiss franc mortgages were very poplular
PM:
I imagine were spitting
NH:
Look at this from Noble Research
NH:
they have been spot on with their calls on IPF
NH:
The conference call will IPF has just ended and beggared belief. It transpires that they didn’t know the extent of the problems in Hungary until yesterday morning. Nor did they realize that so many of their customers had CHF mortgages. They don’t accept that this has any read across for Poland with their survey data suggesting that it only affects 3% of the customer base but how reliable is that data. Also they conceded that in Hungary that a major part of the problem was the outflow of capital caused by such mortgages, this is bound to impact on Poland similarly. Given that this business operates in Emerging Markets, which by there very nature volatile, the inadequacies of their management information is astounding
NH:
Management appear to be completely asleep at the wheel and my suspicion is that there will be further bad news to come. Despite the correction in the share price, barring a dead cat bounce, this stock looks set to continue heading south.
NH:
of course Poland won’t be the same as Hungary
NH:
yep and the analyst Mark Williamson has issued an update this morning
NH:
like your note, he too thinks there is a covenant problem
NH:
On 8 May, IPF released a profit warning highlighting that PBT for FY09 is likely to be c.£20-30m. During the conference call management confirmed that impairments only need to increase by 3% of revenues for IPF to breach its interest cover covenant. The conference call also highlighted the inadequacy of the Group’s credit scoring and management information systems. In the note we discuss what the lenders attitude might be to a breach and what any renegotiation might look like.
We recognise that IPF has a good business model which is highly cash generative and delivers high returns on equity. Using our current forecasts the average Return on equity for next five years is 15%. Assuming a cost of 10% and long term growth rate of 3%, implies a valuation of 155p. However, there are serious question marks around the ability of the management team and hence this significantly increases execution risks and therefore the Group’s real cost of capital of, say, 20% might not be unreasonable, suggesting a valuation of 65p, 31% downside. Furthermore, there is a strong likelihood that IPF might breach its banking covenants. In such a scenario, creditors will be in a position to take control and the fate of equity holders will be left in their hands.
NH:
Given the potential risk of a covenant breach and continuing execution risks, we remain Negative and would recommend that investors avoid the stock. We have withdrawn our formal valuation until clarity on potential breaches of covenants emerge.
PM:
here’s the stuff from Citi
PM:
All eyes on Hungary — IPF expects Hungary to generate £20-£30m less than budgeted PBT in 2009. Poorer credit quality is expected to drive: i) higher impairment charges, and ii) lower revenues, due to less new lending during the year.
Status quo — This assumes collections in Hungary neither worsen nor improve from April levels. Hungary saw worsening collections in Jan-Mar and stabilisation in April. In contrast, the rest of Central Europe saw improvement in Mar-Apr.
GDP forecasts — Citi forecasts -5.3% fall in Hungarian GDP 2009, compared to +1.1% in Poland, -2.1% in the Czech Republic and -4.3% in Romania. Banking covenants — IPF expects to comfortably meet its banking covenants. On our new 2009 PBT forecast of £47m, EBITA interest cover is 2.7x. We estimate PBT would have to fall by £27m to £20m in order to breach its 2x covenant.
The benefit of the doubt — In our new numbers, we assume that IPF only sees a £20m reduction in Hungarian PBT, and that the situation improves enough for risk adjusted revenues to grow again there in 2010. We continue to forecast Mexico breaks even this year and makes double digit PBT in 2010.
100p DCF-based price target — We derive a 103p DCF valuation for IPF, which is fully dependent on 2010 and 2011 recovery. Given the high degree of uncertainty in the near-term, we retain our Hold/High Risk recommendation, but shift our price target from 115p to 100p.
PM:
Actually — its this bit i wanted to put on — on banking covenants
PM:
Management has said today that it is comfortable with all its banking covenants. These are:
Minimum 2x EBITA Interest Cover
Minimum £125m net worth
Maximum 3.75x gearing
Receivables > 1.1x borrowings
The most vulnerable covenant to the Hungarian profit warning and potentially higher impairment charges, in our view, is the interest cover covenant. 2.7x on our forecasts. Taking our £46.9m pre-tax, pre-exceptional forecast and adding back £35.9m finance costs and £15.4m depreciation suggests EBITA of £98.3m. This covers our finance costs forecast by 2.7x.
PM:
£20.5m PBT threshold. In order to breach the 2x cover covenant, EBITA would have to be only 2x our finance costs forecast, or £71.8m. This would be equivalent to PBT of only £20.5m (£71.8m – £15.4m – £35.9m), which is some £26.5m below our forecast.
More aggressive? If, however, we had cut our old £67m group PBT forecast by £30m rather than £20m, i.e. at the most aggressive end of management guidance, our PBT forecast would only be £37m and our interest cover 2.5x. The safety margin of £16.5m in that instance is only equivalent to a 3% point worsening in the group impairment charge as a percentage of revenue. (Management has previously indicated that every 1% shift = £5m PBT). We currently forecast a 6% shift from 23.2% in 2008 to 29% in 2009.
PM:
In the event of covenant breach, IPF would clearly have to seek renegotiation of its covenants with its lenders, in the first instance. If it is able to demonstrate the problem is isolated to Hungary, perhaps some sort of segmentation of the part of the debt relating to Hungary could be achieved. If no renegotiation were possible, the group might be forced to raise additional capital to pay down
some of its debt, and so move back within covenants.
PM:
Something tells me we will be writing more on this company over the coming months
NH:
yeah, I wouldn’t say it was headed to the knackers yard like Cattles
NH:
but they do seem to be in denial
NH:
oh, Sam has just skyped something interesting
NH:
Sebastian Faulks will publish a novel, A Week in December, in which one of his main characters is a hedge-fund manager. Faulks began work on it in 2005, intrigued by the extent to which finance had become divorced from reality.
NH:
anyway, we are going to see more of this, books, films, GQ spreads on the crunch
NH:
crikey, the red card is coming out
NH:
Paul is about to brandish it
PM:
Wel, im just bored with some people picking on other readers — even if those readers can defend themselves
PM:
Just a week’s ban handed out to one person
PM:
Neil — i cant believe it
PM:
We’ve got all the way to 11.55 — and no proper green shoot coverage
NH:
Where’s this Barclays note you did a post on earlier.
PM:
I think it’s in the Long Room now.
PM:
But look, another reader TJB pointed out the JPM global asset allocation note from Friday.
PM:
That’s even better then my one.
NH:
Tracy did something also
PM:
Portfolio strategy –– All trades are correlated. There is only one choice of risk
exposure –– long or short the recovery. We are significantly long the recovery.
• Economics –– The world economy is bottoming. The recovery is set to be a
clean V.
• Fixed Income –– Go tactically short duration in Europe, staying overweight
EMU high yielders.
• Equities –– Positions favour a continuation of the rally.
• Credit –– We expect US HG spreads to tighten further as demand continues
to exceed supply with a year-end target of 275bp
• FX –– Short the USD against cyclical currencies.
• Alternatives –– Hedge funds posted 3.8% return in April. We raise our fullyear
return forecast to 11%. HF AUM will likely finish the year around $1.5tr,
from $1.33tr today, half due to returns, and half to net inflows.
PM:
That’s from Jan Loeys at JPM
PM:
The capitulation on recession trades is in full swing, and is far from over. We thus remain squarely long risky assets in all markets and underweight defensive assets and sectors. There is unfortunately little diversification across markets at this point, and your position really comes down to a single risk
exposure –– long or short the recovery trade.
• Markets are paying little attention to value as price action and flows are dominated by the steady and continued reversal of recession positions. This ought to provide good opportunities to relative value players, but only if they have enough risk capital to withstand indiscriminate buying and selling flows. These flows are the reason we had to cover longs in the bond market, relative to our medium-term positive forecasts. Similarly, we are quite wary of high-yield bonds –– given rising default rates and likely low recoveries ––– and greatly prefer high-grade, but the buying flows are ignoring our value concerns.
PM:
• Towards a “V”. Market participants who are covering recession positions are arguing strongly this is just a bear market rally and the economic rebound will be short-lived. We believe risk is moving towards a stronger recovery. Economists are steadily raising growth forecasts, pushing up risky markets and creating a self reinforcing dynamic. The first few quarters may only show below-trend growth for the world, but risk is moving towards above trend next year. Momentum in opinions and the data are thus set to continue to support risky markets for some time.
PM:
The BarCap stuff is here
NH:
just going back to the earlier stuff on United Utilities
NH:
and utilities generally
PM:
(Lorcan — dont have a garden — just roof terrace)
NH:
Draaisma has just published a note on the sector and he is making it his biggest overweight.
NH:
he doesn’t like all this trash, you see
NH:
Buying Utilities. It is the least popular sector, and we
like its defensive earnings, attractive valuations,
exposure to higher energy prices and improving credit
markets. We are buying RWE, Petrofac, BAE Systems;
selling Henkel, DT, Pearson, K+N.
Pearson plc is the parent company of the Financial Times, publisher of FT Alphaville.
NH:
We are now +4% OW Utilities, +2% OW Telcos, -2%
UW Financials, -4% UW Industrials. We are reducing:
our UW in Financials from -4% to -2%; our UW in
Industrials from -5% to -4%; and are closing active
positions in Staples and Consumer Discretionary (both
from OW) and Energy (from UW).
NH:
Macro improvements have been better than we
expected – we keep an open mind on the outlook.
Policymakers have been more successful than we
thought two months ago. We are impressed by
improving money markets, booming credit and issuance,
and the way the stress test has been digested. As a
result, we increase our MSCI Europe target from 750 to
850, implying 9% downside.
NH:
We reinstate our Market Timing Indicators, which
currently give a neutral signal. Now that authorities
have fought their way back ahead of the curve, we
should re-instate the MTIs. Their current message is
mixed, with the combined indicator in neutral territory –
one component says buy and one says sell.
NH:
The rally may last longer than we thought, but we
still think it is one to sell into. Things that could spell
the end of the rally are a sell signal on the market timing
indicators; a big positive reading on the AAII bulls minus
bears (latest +11); the typical seasonal earnings
downgrade period in the autumn; seasonality in general;
the Westpac indicator of economic surprises peaking
out; or ISM new orders reaching a 50+ reading.
NH:
so he is keeping with his call that this is just a bear market rally that will end
NH:
although one could argue that last bear market rally went on from 2003 till 2007
NH:
so it could be a long wait
NH:
The market is doing its usual job in what we think is a bear
market rally (but we keep an open mind). Someone once
said that the market is a device with the sole purpose of making
the biggest fool out of the biggest number of people, as often
as possible. An investor’s only job, therefore, is to avoid being
that fool. With MSCI Europe having risen 31% from the trough
and with us being underweight for the last 13% of that, one can
only conclude we have been foolish!
Anthony Bolton puts it in his own way in his recent book
Investing Against The Tide. He urges investors to accept that 2
out of every 5 of your decisions will be wrong; to keep an open
mind; to be independent but not stubborn. Other lessons from
his book also resonated with us. He views consensus trades
are the most risky. And he believes the biggest opportunity in
modern markets is for true long-term investors, given the
short-term obsession of today’s investor base.
NH:
few things to round up on
NH:
AstraZeneca good market
NH:
good news on a key drug
NH:
shares up 155p at £25.52
NH:
here’s a bit of comment
NH:
Brilinta (AZ 6140): positive results from the PLATO study
NH:
The group has just published the title of its survival study PLATO, assessing the
compound 6140 (Brilinta) in 18,600 patients, in the treatment of acute coronary syndromes
(myocardial infarction, etc.). The compound is thus aimed at one of the current indications
of Plavix (which accounts for 20% of sanofi-aventis’ global product sales ). The detailed
results will be presented at the ESC (European Society of Cardiology) annual meeting.
n The study has yielded positive results : the compound achieved its primary endpoint, i.e. a
reduction in the number of cardiovascular events in patients with ACS, and a steeper
reduction than with Plavix. These results enabled AZn’s management to confirm that it
should be able to submit the registration file in Q4 09.
n The drug’s efficacy is in no doubt. The phase II trials showed that it greatly inhibits the
action of platelets and is fast-acting, more so than with Plavix. The real question concerns
its tolerance profile: in the phase II trials , the occurrence of bleeding was slightly higher
than with Plavix (10.2% at doses of 90 mg and 180 mg vs. 9.2 mg for Plavix at 75 mg). In
particular, major bleeding events were far more pronounced.
n The share price is likely to react favourably to this announcement. We estimate Brilinta’s
peak sales potential in this indication at $600m.
NH:
Brilinta (AZD6140) PLATO trial meets primary end point — The end point was
a composite of heart attack, stroke or death from cardiovascular cause. The
trial was an 18,000 patient head-to-head comparison with Sanofi-Aventis’
Plavix added on to aspirin for treating acute coronary syndrome (ACS=unstable
angina, acute heart attack). Brilinta showed a statistically significant benefit.
The trial was powered to detect a 13% risk reduction with 90% confidence.
Full data will be presented at the European Society of Cardiology in Barcelona
Aug 29- Sep 2. AZN plans to file registration applications in 4Q09. Assuming
normal FDA processing launch could be in early 2011.
NH:
Brilinta has additional advantage of reversibility — Brilinta has a 12-hour half
life and reversibly blocks ADP receptors on platelets. Plavix is an irreversible
inhibitor. Patients with ACS who require by-pass surgery could have surgery
sooner if Brilinta is used vs. the current 5-day wait to allow Plavix to wash out.
Side effect profile similar to phase II — The overall side effect profile was in
line with that seen in the phase II program where the most notable were
bleeding risk (minor bleeds > Plavix, major bleeds the same), ventricular
pauses (arrhythmia) and breathlessness (6% vs. 2% Plavix). PII trial
discontinuations were 1-4%.
Competition coming — Cangrelor from The Medicines Company (licensed from
AZN) is an IV only reversible inhibitor of platelet aggregation, currently in
phase III with very short half life. It may be favoured by Cath labs given the IV
formulation and rapid onset and offset.
NH:
Current CIRA forecast $470m by 2012 — Our current forecasts assume launch
in 2011 with sales of $293m/$470m/$548m in ‘11E/’12E/’13E including a 50%
risk adjustment. ‘12E forecast is 2% of group sales. If clinically meaningful
superiority over Plavix is confirmed with acceptable safety sales could be 3-4x
higher than we forecast. Sales of $2bn in 2012E at group margin would imply
5% upside to ’12E EPS, or incremental DCF value of 6-8%. The share price
move today (5%) looks about right. Good news but perhaps a little early to rerate
the shares on a higher likelihood of R&D success. Multiple risks remain
PM:
Right — we’ve got to go
PM:
Thanks for joining us today
PM:
And thanks for all the comments
PM:
We wil lbe back tomorrow at 11am
PM:
Well the great bull market will be resumed
NH:
FTSE 100 down 30 points at 4,431
NH:
Taxloss, I rejected one of his comments. but he has not be banned. anymore lip and he will be for a month I think
PM:
Some one else did get a week’s ban. I suspect that will be back